肢端肥大症术后IGF-1检测可替代OGTT监测疾病状态
该研究回顾性分析320例接受手术的GH分泌型垂体腺瘤患者,评估IGF-1替代OGTT监测术后缓解的可靠性。除术后1周外,IGF-1在各时间点ROC曲线下面积均大于0.8。320例中270例仅手术后即达内分泌缓解,其中250例IGF-1正常化,平均正常化时间4.7个月。肿瘤侵及海绵窦及切除不完全分别使IGF-1未正常化风险增加3.1倍和9.0倍。
要点
- 除术后1周外,IGF-1在各时间点评估缓解的AUC均大于0.8。
- 仅手术后270/320例达内分泌缓解,其中250例IGF-1正常化。
- 肿瘤侵及海绵窦或切除不完全显著增加IGF-1未正常化风险。
核心结论
- IGF-1水平是OGTT的可靠替代指标,在肢端肥大症术后状态监测中有价值。
研究设计与样本
- 回顾性研究,纳入320例在Severance医院接受手术切除的GH分泌型垂体肿瘤患者。
- 采用ROC分析验证IGF-1评估缓解的准确性,并用回归分析识别OGTT与IGF-1不一致的相关因素。
主要发现
- 除术后1周外,IGF-1在所有时间点的ROC曲线下面积均大于0.8。
- 320例中270例仅手术后即达内分泌缓解,其中250例IGF-1水平正常化。
- 手术后至IGF-1正常化的平均时间为4.7个月。
- 肿瘤侵及海绵窦时IGF-1未正常化风险增加3.1倍,肿瘤切除不完全时增加9.0倍。
关键数值与推荐
- 除术后1周外,IGF-1评估缓解的ROC曲线下面积均大于0.8。
- 仅手术后内分泌缓解率为270/320例,缓解者中IGF-1正常化为250例。
- 手术后至IGF-1正常化的平均时间为4.7个月。
- 肿瘤侵及海绵窦与切除不完全分别使IGF-1未正常化风险增加3.1倍与9.0倍。
临床怎么用
- 肢端肥大症术后除术后1周外,可用IGF-1替代OGTT监测疾病状态。
- 对肿瘤侵及海绵窦或切除不完全者,应关注IGF-1未正常化的较高风险。
局限性
- 本研究为单中心回顾性研究。
- IGF-1需按年龄和性别校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In the management of growth hormone (GH)-secreting pituitary adenomas, the oral glucose tolerance test (OGTT) has been the gold standard not only for diagnoses but also for the determination of biochemical remission. Insulin-like growth factor-1 (IGF-1) is an essential biomarker, although it should be adjusted for both age and sex. OBJECTIVE: We evaluated whether IGF-1 levels could serve as a reliable alternative to an OGTT for disease monitoring after the surgical treatment of acromegaly. We retrospectively reviewed the medical records of 320 patients who underwent surgical resection of their GH-secreting pituitary tumors at the Severance hospital. Receiver operator characteristic (ROC) analyses were performed to validate the accuracy of IGF-1 levels for the assessment of remission. In addition, regression analyses were performed to identify factors associated with discrepancy between OGTT and IGF-1 levels. RESULTS: Except for 1 week after surgery, ROC analyses showed an area under the curve of greater than 0.8 for IGF-1 at all time points. Of 320 patients, 270 achieved endocrine remission after surgery alone. Among these patients, IGF-1 levels were normalized in 250 patients. The mean duration from surgery to IGF-1 normalization was 4.7 months. Regression analyses demonstrated that risk of failed IGF-1 normalization was increased by 3.1-fold when the tumor invaded the cavernous sinus and increased by 9.0-fold in patients with incomplete tumor removal. CONCLUSION: IGF-1 level is a reliable alternative to OGTT and plays a valuable role in monitoring acromegaly status.
引用
- Jung IH, Choi S, Ku CR, et al. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly. J Clin Endocrinol Metab. 2021. PMID: 33738470. doi:10.1210/clinem/dgab186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。